Coriolis Pharma, a contract research and development organization (CRDO), is expanding its current headquarters to form a new campus as the next step in its growth strategy.

Located in the heart of the biotech hotspot Martinsried, the new Coriolis campus will double the overall capacities to 14,000 square meters. It will include two new buildings (Fraunhoferstrasse 14 and F14b), the current headquarters (F18b) and two additional locations (F8 and F11a). The new campus with interconnected buildings will provide additional lab and office space, giving the company sustainable growth opportunities. The first building will be operational in early 2024, while the completion of the entire campus is planned for 2025.

“Coriolis Pharma is investing strongly in creating new attractive jobs in Martinsried,” said Silvia Steyrer-Gruber, CEO of Coriolis Pharma. “The Coriolis campus will be designed for our employees, offering new workspaces, meeting zones, a conference center and an employee restaurant. We formulate innovation by the way of working together, we formulate innovation and revolutionize formulation development.”

In the first construction phase, a modern lab infrastructure, including multipurpose facilities and office spaces will be established. In a second construction phase, a new facility with an employee restaurant and places of encounter will be built.